Deutsche Bank analyst Andrew Peters maintained a Buy rating on Neurocrine (NASDAQ: NBIX) today and set a price target of $99. The company’s shares opened today at $81.70.
According to TipRanks.com, Peters is a 1-star analyst with an average return of -4.1% and a 41.0% success rate. Peters covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Miragen Therapeutics Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Neurocrine is Strong Buy and the average price target is $107, representing a 31.0% upside.
In a report issued on April 23, Jefferies also maintained a Buy rating on the stock with a $105 price target.
See today’s analyst top recommended stocks >>
Based on Neurocrine’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $71.09 million and GAAP net loss of $41.82 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $78.33 million.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBIX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W.
